



AlzChem Group AG

Andreas Niedermaier, CEO
Dr. Georg Weichselbaumer, CSO

March 19, 2021



DISCLAIMER



Cautionary note regarding forward-looking statements

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the AlzChem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, AlzChem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA

Analyst Presentation Q4/2020



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

HIGHLIGHTS

Summary of business development Q4/2020 Financial Report



Stable growth in NITRALZ® business

Positive development in Perlka® and Dicyandiamide business

Continued high Bioselect® demand

Ongoing growth in Creamino®

Lower commodity prices support earnings

COVID-19:
stable production without
interruptions

Slow recovery of steel and automotive business

Sales and EBITDA above 2019 level, in spite of rough environment

Resilient diversified portfolio

FINANCIAL OVERVIEW Q4/2020



Key figures

AlzChem Group	Q4 2019	Q4 2020	yoy %	2019 1 - 12	2020 1 - 12	yoy %
SALES (in M€)	88.4	100.6	+13.8%	376.1	379.3	+0.8%
EBITDA (in M€)	8.7	12.7	+46.4%	50.1	53.8	+7.4%
EBITDA margin (in %)	9.8%	12.6%	+2.8 pp	13.3%	14.2%	+0.9 pp
Earnings per Share (in €)	0.11	0.48	+337.1%	1.77	1.94	+9.8%

COMMENTS

- 12-month sales slightly above previous year; significant growth of EBITDA in 2020 in spite of pandemic effects
- Lower steel and automotive business mitigated by positive effects from the pharmaceutical sector
- Strong recovery of sales and EBITDA in Q4/2020 after a weaker Q3/2020 and a cautious outlook for the last quarter in our last report

SALES ANALYSIS	DELTA Q4	DELTA 01 - 12
Volume	13.7%	0.4%
Price	1.2%	0.6%
Currency	-1.1%	-0.2%

AGENDA

Analyst Presentation Q4/2020



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

4854-32001/905

• 10722 14-311 172009

Chemical structures and data overlaid on the image:

- Chemical structures: NC(CO)c1ccc(O)c(O)c1, COc1ccc(NC(CO)c2ccc(O)c(O)c2)cc1, COc1ccc(NC(CO)c2ccc(O)c(O)c2)cc1, COc1ccc(NC(CO)c2ccc(O)c(O)c2)cc1
- Labels: OH, NH₂, H₃CO, N, OCH₃
- Table:

Cb = pH[H ⁺]	[OH ⁻]	Alpha	Beta
7.403.98E-08	2.51E-07	0.201	0.799
7.602.51E-08	3.98E-07	0.285	0.715
8.001.00E-08	1.00E-06	0.500	0.500
8.403.98E-09	2.51E-06	0.715	0.285
8.801.58E-09	6.31E-06	0.863	0.137


Analysis: Complete.
Position: #120498 05

The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.


BASICS & INTERMEDIATES SEGMENT

Strong EBITDA development supports overall result


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	17.2%	-1.5%
Price	-0.8%	-0.4%
Currency	-0.6%	-0.1%

COMMENTS

- Q4/2020 sales significantly above previous year
- Strong recovery of business from Q3 to Q4 (COVID-19 effects in automotive and steel industry)
- Supported by strong sales of NITRALZ®, Perlka® as well as DCD
- Stable to decreasing raw material prices and lower electricity prices in comparison to previous year
- Higher EBITDA of ~ 9.0 M€ (previous year 5.2 M€) mainly based on larger sales volumes of higher-value products and favorable raw material prices

SPECIALTY CHEMICALS



The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

CREAMINO

DYHARD[®]

Bioselect[®]

Dormex[®]


Creapure[®]

SPECIALTY CHEMICALS SEGMENT




Strong Q4/2020 could compensate most COVID-19 effects of Q3/2020


SALES




EBITDA



SALES



EBITDA




SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	14.0%	2.9%
Price	2.4%	1.1%
Currency	-1.5%	-0.3%

COMMENTS

- Despite COVID-19 effects (affected mainly automotive industry, steel industry and Creapure® business), growth of 3.7% in sales was possible
- Ongoing high demand for pharma raw materials (Bioselect®)
- Sales volume trend for Creamino® continues to rise
- Sales turnaround (automotive industry, steel industry and Creapure® business) in Q4
- Q4 EBITDA significantly above previous year, following strong sales

OTHER & HOLDING




The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.


OTHER & HOLDING SEGMENT

Service sales largely stable with a slight downward trend


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	-6.2%	-7.1%
Price	2.3%	2.4%
Currency	0.0%	0.0%

COMMENTS


- Overall sales slightly below previous year's level
- Less market demand in maintenance and energy supply
- Higher maintenance costs for infrastructure modernization than in the previous year

BALANCE SHEET

AlzChem Group AG (M€)




ASSETS



- Higher other non-current assets due to major capex projects in Q4/2020
- Positive impact from inventory optimization project
- Other current assets increased due to a higher level of cash and cash equivalents
- Deferred taxes for pension provision increased due to higher pension obligations


LIABILITIES



- Equity ratio increased from 17.9% to 19.4% due to positive earnings
- Higher pension provision due to decline in interest rates
- Lower other non-current liabilities because of regular repayment of long-term loans

CASHFLOW

Positive free cashflow due to strong cash inflow from ongoing operations




COMMENTS

- Strong cash inflow from ongoing operations
- Positive effect of inventory reduction on cashflow from ongoing operations
- Investing cashflow below prior year's level due to main CAPEX projects Creamino® and NITRALZ® in 2019
- Cashflow from financing activities (-11.7 M€) – main effects: scheduled repayment of bank loans (-11.9 M€), dividend payments (-7.6 M€), repayment of lease liabilities (-2.0 M€) and payout of loans (+10 M€)


IMPLEMENTING OPERATING TARGETS

Focus on the key growth drivers



IMPLEMENTING OPERATING TARGETS

Focus on the key growth drivers



INTERMEDIATES FOR PHARMACEUTICAL APPLICATIONS

Product world close to life

As a supplier of raw materials for the diagnostics industry, AlzChem contributes to the production of "corona tests":

AlzChem precursors are used both in tests for the detection of SARS-CoV-2 and in tests for the detection of antibodies.

BIOSELECT®



High-purity guanidine hydrochloride and guanidine thiocyanate are used to denature proteins in the development and production of biopharmaceuticals and their generic versions, the biosimilars.

They are also useful reagents for the extraction of DNA and RNA in molecular diagnostics.



METFORMIN/DCD

Diabetes is considered a widespread disease and affects more than 8 million people in Germany, around 90% of whom suffer from type 2 diabetes.¹

Our pharmaceutical intermediate dicyandiamide is an important building block for the world's best-known type 2 diabetes drug metformin (drug substance).

¹Source:
https://www.diabetesde.org/ueber_diabetes/was_ist_diabetes_/diabetes_in_zahlen



NITRALZ®

Our NITRALZ® products are used as raw materials for the production of various APIs (= active pharmaceutical ingredients), including the long-established drug group 'sartans' on the world market.

Sartans have a blood pressure lowering effect and are used in the treatment of cardiovascular and also kidney diseases. Our advanced distillation process provides us with a reliably high standard of quality and purity, which is essential for their use in active ingredients.

INTERMEDIATES FOR PHARMACEUTICAL APPLICATIONS



Back to Europe - Your Benefit



RELIABILITY &
HIGH QUALITY



OUR CUSTOMER
ORIENTATION



OUR KNOW-HOW



SUSTAINABILITY,
HEALTH &
SAFETY




INNOVATION


SUSTAINABLE ALZCHEM



Calcium Cyanamide changes agriculture with – EMINEX®




HOW A NEWLY DISCOVERED APPLICATION CAN PERMANENTLY CHANGE AGRICULTURE



CARBON FOOTPRINT CALCULATION

Global warming potential (GWP) change by addition of 2,2 kg EMINEX® per m³ slurry



Source: Dekra SE, ATB Potsdam

ALZCHEM STRATEGY

Ingredients for profitable growth




SUSTAINABLE ALZCHEM

Sustainability serves us as a guideline for a profitable future



AGILE ALZCHEM

We see change as an opportunity and use it consistently



EFFICIENT NCN

The NCN family tree is the basis of our further development
Profitable - Innovative - Flexible



CUSTOMER-FOCUSED ALZCHEM


We place a worldwide proactive customer focus/orientation at the heart of everything we do




OUTLOOK 2021

Stable development to strong increase in sales and EBITDA forecast (M€)

SALES



EBITDA



COMMENTS

- Further growth of NITRALZ® business
- Expansion of Creamino® business
- Reinforcement of custom manufacturing
- Stable development in the agriculture sector
- Focus on pharma raw materials (Bioselect®)
- Duration of recovery in the automotive and steel sectors challenging to forecast
- Higher raw material prices impact earnings

FINANCIAL CALENDAR

Upcoming dates



2021	MAR 30 – APR 1	Jefferies Pan-European Mid-Cap Virtual Conference
2021	MAY 6	Quarterly Statement 1 st Quarter 2021
2021	MAY 12	Annual General Meeting 2021
2021	MAY 17 – 19	Virtual Spring Conference 2021
2021	AUG 5	Half-Year Financial Report 2021
2021	SEP 6 – 7	Fall Conference 2021, Frankfurt
2021	SEP 21 + 23	Baader Investment Conference
2021	SEP 22	Berenberg and Goldman Sachs Tenth German Corporate Conference
2021	NOV 11	Quarterly Statement 3 rd Quarter 2021
2021	NOV 22 – 24	Deutsches Eigenkapitalforum
2021	DEC 6 – 9	Berenberg European Conference
2021	DEC 7 – 8	MKK – Münchner Kapitalmarkt Konferenz





1,631

EMPLOYEES
(PY 1,623)

M€
~379
SALES
(PY ~376)

M€
~54
EBITDA
(PY ~50)


M€
~49
OPERATING
CASHFLOW
(PY ~44)



ALZCHEM
PRODUCTS
ARE SOLD
WORLDWIDE

INNOVATION SINCE

1908



*All financial indicators relating to
YTD 2020/12 figures and YTD PY*



THANK YOU
FOR YOUR ATTENTION!

CONTACT

Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

WWW.ALZCHEM.COM

AGENDA

Analyst Presentation Q3/2020



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

BALANCE SHEET

AlzChem Group




ALZCHEM GROUP (IN T€)	31.12.2019	31.12.2020	Deviation	
Intangible assets	1,541	1,810	269	17.5%
Tangible assets	165,702	175,062	9,360	5.6%
Investment properties				
Right of use (assets)	9,770	8,524	-1,246	-12.8%
Investments accounted for using the equity				
Financial assets	20	20		
Trade receivables				
Other receivables	470	630	159	33.9%
<i>there of Deferred tax assets for pensions</i>				
Deferred tax assets	34,477	35,795	1,318	3.8%
SUM NON-CURRENT ASSETS	211,981	221,842	9,861	4.7%
Inventories	74,607	67,402	-7,205	-9.7%
Trade receivables	32,501	33,124	623	1.9%
Financial assets	0	0	0	2.3%
Other receivables	14,051	13,501	-550	-3.9%
Income tax receivables	381	1,311	930	244.1%
Cash and cash equivalents	9,061	17,117	8,056	88.9%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	130,602	132,456	1,854	1.4%
SUM ASSETS	342,583	354,298	11,715	3.4%

ALZCHEM GROUP (IN T€)	31.12.2019	31.12.2020	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	69,294	81,356	12,062	17.4%
Other comprehensive income	-48,152	-53,077	-4,925	10.2%
SHARE TO THE SHAREHOLDERS	59,757	66,895	7,137	11.9%
Non-controlling interests	1,592	1,763	171	10.7%
SUM EQUITY	61,350	68,658	7,308	11.9%
Provisions for pensions	134,629	141,775	7,146	5.3%
Other provisions	22,404	24,233	1,829	8.2%
Loans	50,747	48,042	-2,704	-5.3%
Finance lease liabilities	7,710	6,680	-1,030	-13.4%
Trade liabilities				
Other liabilities	513	342	-171	-33.3%
Deferred tax liabilities	4,745	4,695	-50	-1.0%
SUM NON-CURRENT LIABILITIES	220,748	225,767	5,020	2.3%
Other provisions	1,732	2,877	1,145	66.1%
Loans	11,935	12,704	769	6.4%
Finance lease liabilities	1,706	1,634	-72	-4.2%
Finance liabilities		0	0	
Trade liabilities	24,069	20,880	-3,189	-13.2%
Other liabilities	19,172	21,583	2,411	12.6%
Income tax liabilities	1,870	193	-1,677	-89.7%
SUM CURRENT LIABILITIES	60,485	59,872	-613	-1.0%
Sum EQUITY AND LIABILITIES	342,583	354,298	11,715	3.4%

PENSION ACCOUNTING (IFRS)

AlzChem Group (M€)



COMMENTS

- Adjustment of market interest rate from 0.90% → 0.50% increased provision
- Slowly increasing cash payments

INCOME STATEMENT

AlzChem Group



ALZCHEM GROUP (IN T€)	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Deviation (Q4)	YTD Dez. 19	YTD Dez. 20	Dev. YOY
Revenue	92,123	96,120	99,431	88,398	94,740	102,511	81,373	100,634	12,235 14%	376,072	379,257	3,185 4%
Increase (+) / Decrease (-) in inventories of finished goods	7,895	-321	-11,883	-553	2,152	-3,162	3,295	-4,800	-4,247 768%	-4,862	-2,514	2,348 -424%
Other income	4,427	6,114	3,670	2,936	2,425	2,648	2,732	2,866	-70 -2%	17,147	10,671	-6,476 -221%
Raw materials and consumables used	-39,541	-38,320	-33,416	-31,112	-35,491	-35,253	-29,903	-31,860	-748 2%	-142,391	-132,507	9,883 -32%
Employee benefits expense	-30,666	-31,497	-29,313	-30,614	-32,509	-31,733	-29,033	-34,133	-3,519 11%	-122,090	-127,409	-5,319 17%
Other expense	-21,007	-17,473	-14,925	-20,395	-19,002	-18,190	-16,477	-20,024	371 -2%	-73,800	-73,693	107 -1%
EBITDA	13,231	14,623	13,564	8,659	12,315	16,822	11,986	12,683	4,023 46%	50,078	53,806	3,728 43%
Depreciation expense	-4,297	-4,302	-4,964	-5,930	-5,582	-5,742	-5,669	-6,104	-175 3%	-19,492	-23,097	-3,604 61%
Impairment												
EBIT	8,934	10,321	8,601	2,730	6,734	11,080	6,318	6,578	3,849 141%	30,585	30,709	124 5%
Investment income	8	54	26	14	5	20	103	6	-8 -56%	102	134	33 238%
Other interest and similar income	37	55	24	84	620	-453	14	10	-74 -89%	200	191	-9 -11%
Other interest and similar expense	-1,214	-1,537	-2,359	-287	-874	-925	-1,088	-948	-661 230%	-5,396	-3,835	1,561 -544%
Financial result	-1,169	-1,428	-2,309	-190	-248	-1,358	-971	-932	-743 392%	-5,094	-3,510	1,585 -836%
Result from associates												
Result from ordinary business	7,766	8,893	6,292	2,540	6,485	9,721	5,347	5,646	3,106 122%	25,491	27,199	1,709 67%
Taxes on income and profit	-2,212	-2,510	-1,242	-1,381	-2,063	-2,970	-1,542	-759	622 -45%	-7,345	-7,334	12 -1%
<i>thereof income tax</i>	-2,034	-2,653	-1,651	-1,592	-1,630	-3,300	-1,241	-814	779 -49%	-7,930	-6,985	945 -59%
<i>thereof change from deferred taxes</i>	-179	143	409	211	-433	330	-301	55	-157 -74%	584	-349	-933 -441%
Annual result	5,553	6,383	5,050	1,159	4,422	6,752	3,805	4,887	3,728 322%	18,145	19,866	1,720 148%
<i>thereof minority interests</i>	43	43	43	43	43	43	43	43		171	171	
<i>thereof shares held by shareholders</i>	5,510	6,340	5,008	1,116	4,380	6,709	3,762	4,844	3,728 334%	17,974	19,695	1,720 154%
Result per share in EUR	0.54 €	0.62 €	0.49 €	0.11 €	0.43 €	0.66 €	0.37 €	0.48 €		1.77 €	1.94 €	

INCOME STATEMENT

AlzChem Group



ALZCHEM GROUP (IN T€)

	Q4 2019	Q4 2020	Deviation (QoQ)		YTD Dez.2019	YTD Dez.2020	Deviation (YoY)	
Revenue	88,398	100,634	12,235	13.8%	376,072	379,257	3,185	0.8%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	-553	-4,800	-4,247	767.7%	-4,862	-2,514	2,348	-48.3%
Other income	2,936	2,866	-70	-2.4%	17,147	10,671	-6,476	-37.8%
Raw materials and consumables used	-31,112	-31,860	-748	2.4%	-142,391	-132,507	9,883	-6.9%
Employee benefits expense	-30,614	-34,133	-3,519	11.5%	-122,090	-127,409	-5,319	4.4%
Other expense	-20,395	-20,024	371	-1.8%	-73,800	-73,693	107	-0.1%
EBITDA	8,659	12,683	4,023	46.5%	50,078	53,806	3,728	7.4%
Depreciation expense	-5,930	-6,104	-175	2.9%	-19,492	-23,097	-3,604	18.5%
Impairment	0	0	0		0	0	0	
EBIT	2,730	6,578	3,849	141.0%	30,585	30,709	124	0.4%
Investment income	14	6	-8	-55.5%	102	134	33	32.1%
Other interest and similar income	84	10	-74	-88.5%	200	191	-9	-4.5%
Other interest and similar expense	-287	-948	-661	230.3%	-5,396	-3,835	1,561	-28.9%
Financial result	-190	-932	-743	391.7%	-5,094	-3,510	1,585	-31.1%
Result from associates	0	0	0		0	0	0	
Result from ordinary business	2,540	5,646	3,106	122.3%	25,491	27,199	1,709	6.7%
Taxes on income and profit	-1,381	-759	622	-45.0%	-7,345	-7,334	12	-0.2%
<i>thereof income tax</i>	-1,592	-814	779	-48.9%	-7,930	-6,985	945	-11.9%
<i>thereof change from deferred taxes</i>	211	55	-157	-74.2%	584	-349	-933	-159.7%
Annual result	1,159	4,887	3,728	321.6%	18,145	19,866	1,720	9.5%
<i>thereof minority interests</i>	43	43	0	0.0%	171	171	0	0.0%
<i>thereof shares held by shareholders</i>	1,116	4,844	3,728	334.0%	17,974	19,695	1,720	9.6%
Result per share in EUR	0.11 €	0.48 €	0	321.6%	1.78 €	1.95 €	0	9.5%

CASH FLOW

AlzChem Group



CASHFLOW (IN M€)

	Q4 2019	Q4 2020	1 - 12 2019	1 - 12 2020
Consolidated earnings before taxes	2,541	5,644	25,492	27,198
Depreciation on fixed and intangible assets	5,929	6,104	19,492	23,097
Decrease in pension provisions	-234	-281	-1,005	-1,182
Loss (+) / Profit (-) from the sale of non-current assets	-31	0	-45	-3
Other non-cash income (-) and expenses (+)	-2,039	5,285	6,246	7,857
Financial result	189	933	5,094	3,510
Interests & Taxes	-2,211	-2,141	-7,282	-11,500
Increase (+) / Decrease (-) Net Working Capital	13,917	-621	-4,360	-267
Cashflow from ongoing operations (Net cash flow)	18,061	14,923	43,631	48,710
Cash outflows for investments in fixed assets	-9,106	-12,803	-41,382	-28,832
Cash inflows from the sale of fixed assets	4	-2	55	3
Cash inflow from the acquisition / Reverse acquisition				
Cashflow from investing activity	-9,102	-12,804	-41,327	-28,829
Free cashflow	8,959	2,119	2,304	19,881
Deposits (+) / Repayment (-) bank loans long-term		10,000	30,102	10,000
Repayment of bank loans long-term	-3,226	-2,983	-7,185	-11,934
Deposits (+) / Repayment (-) from short-term financing lines	-6,099	-4,001	-18,166	-1
Dividend payments			-9,159	-7,632
Payment of reduction in leasing liabilities	-474	-610	-1,594	-1,996
Payment of transaction costs of capital increases				
Payments to non-controlling interests		0	-171	-171
Cashflow from financing activity	-9,799	2,406	-6,173	-11,734
Net increase / decrease in cash and cash equivalents	-840	4,525	-3,869	8,147

SEGMENT OVERVIEW BY QUARTER

AlzChem Group



SALES	2018				2019				2020				Deviation PY (Q4) T€ %		YTD Q4 2020		Deviation PY (YOY) T€ %	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€			PY T€	Actual T€		
Basics & Intermediates	34,155	36,926	35,896	32,989	35,465	37,844	41,693	34,405	36,012	38,266	32,320	39,837	5,431	14%	149,408	146,434	-2,973	-2%
Specialty Chemicals	53,917	56,817	49,805	48,876	50,063	51,686	50,952	47,321	52,199	57,854	42,995	54,383	7,062	13%	200,022	207,431	7,409	4%
Other and Holding	6,450	6,971	6,259	6,145	6,595	6,591	6,786	6,672	6,529	6,391	6,058	6,414	-258	-4%	26,643	25,392	-1,251	-5%
Group Consolidation	5				0										0		0	-100%
AlzChem Group	94,522	100,719	91,960	88,010	92,124	96,120	99,430	88,398	94,740	102,511	81,373	100,634	12,235	12%	376,072	379,257	3,185	1%

EBITDA	2018				2019				2020				Deviation PY (Q4) T€ %		YTD Q4 2020		Deviation PY (YOY) T€ %	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€			PY T€	Actual T€		
Basics & Intermediates	1,060	188	106	-2,242	1,038	628	3,220	360	1,903	2,485	2,006	2,587	2,227	86%	5,247	8,981	3,734	71%
Specialty Chemicals	12,648	16,128	9,485	12,431	11,711	12,919	9,218	7,837	10,158	14,457	9,418	10,092	2,256	22%	41,684	44,125	2,441	6%
Other and Holding	759	-262	547	-852	357	838	1,435	1,877	317	81	361	230	-1,647	-715%	4,506	989	-3,518	-78%
Group Consolidation	589	-152	265	-1,341	125	239	-309	-1,414	-63	-201	202	-227	1,187	-523%	-1,359	-289	1,070	-79%
AlzChem Group	15,057	15,902	10,402	7,996	13,231	14,623	13,564	8,659	12,315	16,822	11,986	12,683	4,023	32%	50,078	53,806	3,728	7%

EXECUTIVE TEAM

AlzChem Group AG



KLAUS ENGLMAIER, COO

WITH ALZCHEM SINCE 1988

AREAS OF RESPONSIBILITY Production, Engineering, Environment/Safety/Health/Quality, Technology

ANDREAS NIEDERMAIER, CEO

WITH ALZCHEM SINCE 1999

AREAS OF RESPONSIBILITY Company Strategy, Finance & Controlling, Investor Relations & Communication, IT, Risk Management, HR, Supply Chain Management, Legal/Patents & Trademarks

DR. GEORG WEICHSELBAUMER, CSO


WITH ALZCHEM SINCE 2012

AREAS OF RESPONSIBILITY Marketing, Sales, Innovation Management & Process Development, R&D, Product Safety and Approval




ALZCHEM GROUP LOCATIONS

Production sites and sales companies



Fully Integrated Business Model (“Verbund” System)

Ability to adapt production to satisfy changing end market needs



BENEFITS OF “VERBUND”

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

MEGATRENDS AS GROWTH DRIVERS

Growth of the population



Healthy aging



Sustainability






OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO	A feed additive for broilers and pigs	Feed additive
	Creapure®	Premium brand for creatine monohydrate as a food supplement in sports nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU® S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Alzogur®	Biocide for the prevention of diseases in animal production	Agriculture
	Silzot® SQ	Silicon nitride powder for the solar industry	Photovoltaics
	Silzot® HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine hydrochloride salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for agrochemical products	Various

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD [®]	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	 NITRALZ [®]	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Perlka [®]	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Operation of the Trostberg Chemical Park (companies located at the site: AlzChem, BASF, Firmenich, Aramark, VIActiv, Degussa Bank)		
	Site services		
	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		


KEY SHARE DATA

Share Details as of March 17, 2021



SHARES OUTSTANDING	10,176,335
LAST CLOSING PRICE	EUR 25.10
MARKET CAPITALIZATION	EUR 255.4 m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
DESIGNATED SPONSOR	Baader Bank AG Oddo Seydler Bank AG

SHAREHOLDER STRUCTURE



** Information regarding the free float in accordance with section 2.3 of the „Guide to the DAX Equity Indices“, as amended.*